Results 11 to 20 of about 6,459 (257)

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide

CPT: Pharmacometrics & Systems Pharmacology
Tirzepatide is a first‐in‐class glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist approved as for the treatment of type 2 diabetes mellitus.
Karen Schneck, Shweta Urva
doaj   +2 more sources

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management

Journal of Obesity & Metabolic Syndrome, 2023
The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss.
Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, Melanie J. Davies   +3 more
doaj   +3 more sources

Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis [PDF]

Obesity Science & Practice
Background Endogenous glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) regulate islet cell function. GLP‐1 receptor agonists (GLP‐1RAs) have been associated with an elevated risk of acute pancreatitis.
A. B. M. Kamrul‐Hasan, Sunetra Mondal, Deep Dutta, Lakshmi Nagendra, Mohammed Ruhul Kabir, Joseph M. Pappachan   +5 more
doaj   +2 more sources

Appendicitis After Initiation of Tirzepatide

Diabetes, Metabolic Syndrome and Obesity
Garrett Chan1, Mariam Ansar1, Marlena Klein1,21Department of Internal Medicine, Cooper University Hospital, Camden, New Jersey, USA; 2Cooper Medical School of Rowan University, Camden, New Jersey, USACorrespondence: Garrett Chan, Email chan-garrett ...
Chan G, Ansar M, Klein M
doaj   +2 more sources

Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States

Diabetes, Metabolic Syndrome and Obesity
Sriya Amruta Kosaraju,1 Rong M Zhang2 1Department of Biomedical Sciences, University of Missouri-Kansas City, Kansas City, MO, USA; 2Department of Medicine-Division of Endocrinology, Washington University, St Louis, MO, USACorrespondence: Rong M Zhang ...
Kosaraju SA, Zhang RM
doaj   +2 more sources

A potential association between tirzepatide and hypercalcemia in the setting of chronic hydrochlorothiazide use

Endocrinology, Diabetes & Metabolism Case Reports
Hypercalcemia is a prevalent electrolyte disturbance commonly associated with primary hyperparathyroidism, cancer, or medication adverse effects. Thiazide diuretics reduce urinary calcium excretion, increasing calcium reabsorption and hypercalcemia ...
Basil Nduma, Sai Nikhitha Malapati, Veeranna Vibhuti   +2 more
doaj   +2 more sources

Tirzepatide Versus Long-Acting Insulin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Journal of Diabetology
Introduction: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like-peptide-1 receptor agonist (GLP-1 RA), has emerged as a promising option for managing type 2 diabetes.
Mohamed A. Abu-Alsaud, Mohamed Ellebedy, Noha Hammad, Mina I. Lamie, Ahmed F. El-Rawy   +4 more
doaj   +2 more sources

Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review

Obesities
Obesity represents a global health challenge, with a critical and urgent need for long-term, sustainable management strategies. Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor ...
Mohammed Sallam, Johan Snygg, Sara El Ghandour, Malik Sallam   +3 more
doaj   +2 more sources

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis [PDF]

, 2022
Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its association with cardiovascular outcomes requires evaluation. This pre-specified cardiovascular meta-
McGuire, Darren K., Zoungas, Sophia, Wiese, Russell J., Sattar, Naveed, Weerakkody, Govinda J., Nishiyama, Hiroshi, Pavo, Imre   +6 more
core   +1 more source

Tirzepatide: A Systematic Update

, 2022
Tirzepatide is a new molecule capable of controlling glucose blood levels by combining the dual agonism of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors.
Gaetano Santulli, Santulli, Gaetano, Varzideh, Fahimeh, Pasquale Mone, Imma Forzano, Mone, Pasquale, Avvisato, Roberta, Roberta Avvisato, Fahimeh Varzideh, Forzano, Imma, Stanislovas S. Jankauskas, Jankauskas, Stanislovas S.   +11 more
core   +1 more source